scholarly journals Molecular Insights into Psychedelic Drug Action

2021 ◽  
Author(s):  
Samuel T. Slocum ◽  
Jeffrey F. DiBerto ◽  
Bryan L. Roth
Keyword(s):  
2018 ◽  
Vol 25 (24) ◽  
pp. 2764-2782 ◽  
Author(s):  
Erica Valencic ◽  
Alenka Smid ◽  
Ziga Jakopin ◽  
Alberto Tommasini ◽  
Irena Mlinaric-Rascan

Human primary immunodeficiency diseases (PIDs) are a large group of rare diseases and are characterized by a great genetic and phenotypic heterogeneity. A large subset of PIDs is genetically defined, which has a crucial impact for the understanding of the molecular basis of disease and the development of precision medicine. <p> Discovery and development of new therapies for rare diseases has long been de-privileged due to the length and cost of the processes involved. Interest has increased due to stimulatory regulatory and supportive reimbursement environments enabling viable business models. <p> Advancements in biomedical and computational sciences enable the development of rational, designed approaches for identification of novel indications of already approved drugs allowing faster delivery of new medicines. Drug repositioning is based either on clinical analogies of diseases or on understanding of the molecular mode of drug action and mechanisms of the disease. All of these are the basis for the development of precision medicine.


2015 ◽  
Vol 13 (10) ◽  
pp. 1722-1739 ◽  
Author(s):  
Niki Antypa ◽  
Raffaella Calati ◽  
Alessandro Serretti

2020 ◽  
Vol 37 (12) ◽  
pp. 1261-1279 ◽  
Author(s):  
Neil M. Weston ◽  
Damian Gibbs ◽  
Catherine I. V. Bird ◽  
Aster Daniel ◽  
Luke A. Jelen ◽  
...  

2021 ◽  
Author(s):  
Wenbo Zhang ◽  
Xiaoying Li ◽  
Xiaolei Zhang ◽  
Yan Dong ◽  
Lianghai Hu

Quantitative proteomics combined with thermostability assay provide a novel strategy for the study of mechanisms on drug action and resistance.


2019 ◽  
Vol 5 ◽  
Author(s):  
Mary J. Maclean ◽  
W. Walter Lorenz ◽  
Michael T. Dzimianski ◽  
Christopher Anna ◽  
Andrew R. Moorhead ◽  
...  

AbstractLymphatic filariasis (LF) threatens nearly 20% of the world's population and has handicapped one-third of the 120 million people currently infected. Current control and elimination programs for LF rely on mass drug administration of albendazole plus diethylcarbamazine (DEC) or ivermectin. Only the mechanism of action of albendazole is well understood. To gain a better insight into antifilarial drug actionin vivo, we treated gerbils harbouring patentBrugia malayiinfections with 6 mg kg−1DEC, 0.15 mg kg−1ivermectin or 1 mg kg−1albendazole. Treatments had no effect on the numbers of worms present in the peritoneal cavity of treated animals, so effects on gene expression were a direct result of the drug and not complicated by dying parasites. Adults and microfilariae were collected 1 and 7 days post-treatment and RNA isolated for transcriptomic analysis. The experiment was repeated three times. Ivermectin treatment produced the most differentially expressed genes (DEGs), 113. DEC treatment yielded 61 DEGs. Albendazole treatment resulted in little change in gene expression, with only 6 genes affected. In total, nearly 200 DEGs were identified with little overlap between treatment groups, suggesting that these drugs may interfere in different ways with processes important for parasite survival, development, and reproduction.


1982 ◽  
Vol 68 (3) ◽  
pp. 353 ◽  
Author(s):  
David R. Semeyn ◽  
Ralph A. Pax ◽  
James L. Bennett

Sign in / Sign up

Export Citation Format

Share Document